About: Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.21 (+0.84%)
GANX NASDAQ Gain Therapeutics Inc
Gain Therapeutics Inc share price
Atividade de preço de GANX
Último preço
$ 1,210
Variação (24h)
0,01 USD (0,84%)
Volume
70.17K
Volume (média 4 sem.)
-
Abertura
$ 1,20
Variação do dia
$ 1,20 - $ 1,25
Fechamento anterior
$ 1,20
Último negócio
29 Oct, 4:01 pm GMT+0
Atrasado
29 Oct, 4:01 pm GMT+0
GANX price performance
Atrasado
29 Oct, 4:01 pm GMT+0
quote.marketSignals